Loading…
Loading…
Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market. Lucosky Brookman LLP To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC"), conducting necessary due diligence related to the registration statement, preparation and filing of responses to SEC comments and any related amendments, preparation and filing of the Company's application for listing of its securities on a nationally recognized securities exchange (including responses to comments and amendments), and assisting with general corporate matters related to the registration statement and listing application.
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission. Inline Viewer: ADIA NUTRITION, INC.
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m.
Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives.
Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the study's ongoing, staggered enrollment schedule.
New Platform Now Live, Featuring Expanded Sections on Clinical Studies, Stem Cell Therapies, Aesthetics, Media, Podcasts, Case Studies, and Investor Resources Winter Park, Florida--(Newsfile Corp. - July 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine company, today announced the launch of its redesigned corporate website. The redesigned website is now live, with the project still in progress and active changes and improvements currently being made.
Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO.
Name change to appear on Daily List today following expedited review; trading begins tomorrow Winter Park, Florida--(Newsfile Corp. - July 9, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) announced today that FINRA has processed its corporate name change to Adia Med Inc. on an expedited timeline. The name change will be reflected on the FINRA Daily List today, with trading under the new name expected to begin tomorrow, Friday, July 10, 2026, on the OTC Markets.